Product pipeline
Lead candidate Mangoral (Phase III) is an MRI imaging drug being developed for detection and localization of liver metastases.
Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.
Events
- February 10 - February 11
Swiss Nordic Bio 2021
- February 16 @ 08:00
Full-year financial report 2020 (Jan-Dec)
- March 23 - March 24
Stockholm Corporate Finance Life Science seminarium
- May 5 @ 14:00 - 16:00
Annual General Meeting 2021
- May 12 @ 08:00
Interim Report Q1 2021 (January-March 2021)
Latest news
- 2021-01-14Information regarding transfer of shares in Ascelia Pharma AB from CMC SPV
- 2021-01-12Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy
- 2020-12-15Ascelia Pharma gets US patent for second generation Mangoral
- 2020-12-02New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent
- 2020-11-13Ascelia Pharma included in the global stock market index MSCI World Micro Cap